Physiolite infusion solution
SUBSTANCE: what is declared is an infusion solution for filling the deficiency and meeting the physiological needs for water and basic electrolytes, which contains the following ingredients: sodium (Na+) - 27.72-28.28 mmole/l; fumarate(H2C4O4 2-) - 13.86-14.14 mmole/l; potassium (K+) - 18.61-18.99 mmole/l; calcium (Ca2+) - 3.56-3.64 mmole/l; magnesium (Mg2+) - 2.18-2.22 mmole/l; chlorine (Cl-) - 30.0-30.6 mmole/l; glucose (C6H12O6) - 189.1-192.9 mmole/l, water for injections.
EFFECT: solution contains the basic electrolyte concentration balanced for meeting the physiological needs; it is safe for the clinical application and can be used in diseases of various aetiology for patients of any age.
1 tbl, 2 ex
The invention relates to medicine, namely to infusion therapy for the shortfall and ensure physiological water needs and basic electrolytes.
Known multicomponent infusion solution ringer-acetate (JSC "Firm metroliner")containing sodium acetate, sodium chloride, potassium and calcium (Griffith CA. The family of Ringer''s solutions. J Nati Intravenous Therap Assoc 1986; 9:480-483).
The use of this solution in the singular to ensure physiological needs in the basic electrolyte is invalid because its scope is limited to the body's need for sodium. The concentration of sodium per liter of solution, ringer-acetate equal to 135 mmol/L. Physiological need for sodium, for example, for a child 10 years of age is 1 to 2 mmol/l, i.e., not more than 60 mmol per day. Overdose of sodium ions causes a delay in the body of water and, consequently, to the development of edema, disturbance of microcirculation, which may adversely affect the course of the disease.
Solution volume of ringer-acetate should not exceed 450 ml, while the daily volume is within 1700-2100 ml. Missing daily volume of the liquid should not contain sodium, and it is necessary to introduce an aqueous solution of glucose. In addition, the low concentration of potassium, calcium and magnesium in solution, ringer-acetate requires additional use of the Oia their concentrated solutions, which are glucose solution.
Similar features is characterized by a known solution of Sterofundin G5 (Reference Vidal 2013. Drugs in Russia. Vidal 2013). The contents of sodium and chloride in this solution even more than the above: 140 mmol/l and 127 mmol/l, respectively.
There are several variants of child solution Monastery, but they lack magnesium ions and acetate ("Infusion therapy and clinical nutrition" / Under the editorship of Professor G. N. Habich, Fresenius AG, Germany, 1992).
Known sodium chloride 0.22% solution in combination with 5% glucose solution, which contains 20 mmol potassium (Ann G. Bailey et al. Perioperative Crystalloid and Colloid Fluid Management in Children: Where Are We and How Did We Get Here? // Anesth. Play mode display. - 2010. - Feb. - Vol.110, No. 2. - P. 375-390). This solution contains no calcium or magnesium.
A known solution of sodium chloride 0.18% in solution, 4% glucose, containing 30 mmol of sodium and chlorine (Pocket book of Hospital care for children. Geneva, WHO, 2005). The disadvantage of this solution is that it only consists of 3 components and water, and this is not enough to ensure physiological needs basic electrolytes.
Closest to the claimed infusion is a solution of Normotonic G5 containing sodium acetate, sodium chloride, potassium, calcium, magnesium and glucose (Gerasimov, L. C., frost, C. C. "Water-electrolyte and acid-base balance in patients in CR the political conditions". General reanimatology, 2008, No. 4, S. 79-85).
The disadvantage of the solution, selected as a prototype, are too high concentrations of sodium and chlorine: 100 mmol/l and 90 mmol/l, respectively. Such concentrations of sodium and chlorine limit the daily volume of the solution to one liter, while the daily fluid needs adult - an average of 2.5 liters. In result you will need to enter an aqueous solution of glucose in a volume of 1.5 l to achieve the total required amount of fluid. In children, the daily dose of this solution should be between 20 to 30 ml/kg depending on age and physiological needs in ions of sodium and chlorine, and the volume of fluid necessary to Supplement water glucose solution, containing sodium and chlorine ions.
Thus, the solution of Normotonic G5 can not only be used for total intravenous provision of physiological water needs and basic electrolytes.
Another disadvantage of the prototype is that the concentration of glucose molecules in the solution is relatively high and amounts to 55 g/l, which limits the speed of its introduction and eliminates the possibility of use in the operating room, under conditions of General anesthesia because of the risk of hyperglycemia.
You should conclude that none of the known electrolytic races the thieves can not only be used to provide physiological water needs and basic electrolytes. To perform this task we need to combine one of the sodium solution with an aqueous solution of glucose, in which, as an emergency measure, is added to concentrated solutions of potassium, calcium and magnesium.
The objective of the invention is a balanced deficit reduction and the maintenance of physiological water needs and basic electrolytes by using one multi-component solution.
According to the present invention, the technical solution of the task is achieved by the infusion solution to fill the gap and provide physiological water needs and basic electrolytes containing chlorides of potassium, calcium, magnesium and glucose, the concentration of the components is, mmol/l:
|Calcium (CA2+)||3,56-of 3.64|
|Water for injection||rest|
Sodium concentration less than 28 mmol/l may lead to a decrease in the concentration of sodium in the blood plasma, the development of excitation, the occurrence of muscle spasms and cramps. Excess sodium concentration more than 28 mmol/l can lead to an overdose of sodium with the development of edema interstice, circulation and nutrition of the cells.
The concentration of potassium is less of 18.8 mmol/l may lead to a decrease in the concentration of potassium in the blood plasma, weakness of skeletal muscles, including respiratory, decrease intestinal motility, depression of consciousness. The excess concentration of potassium more than 18.8 mmol/l may lead to increased concentration of potassium in plasma, development of cardiac arrhythmias, the occurrence of ventricular fibrillation and asystole.
The calcium concentration of less than 3.6 mmol/l may lead to a decrease in the concentration of calcium in the blood plasma, development of muscle spasm, hypertonicity of muscles, until the development of seizures. Excess calcium concentration of 3.6 mmol/l may lead to increased concentrations of calcium in the plasma, the development of disorders in the Central nervous system (drowsiness, depression, psychosis, ataxia, stupor, and coma), muscle weak the STI, hypertension, bradycardia and asystole.
The concentration of magnesium is less than 2.2 mmol/l may lead to a decrease in the concentration of magnesium in plasma, development of persistent high blood pressure, heart rhythm problems, spasms and convulsions. The higher concentration of magnesium than 2.2 mmol/l may lead to increased concentration of magnesium in plasma, the development of arterial hypotension, respiratory depression and loss of consciousness.
The chlorine concentration of less than 30.3 mmol/l may reduce the chlorine concentration in plasma, renal failure and azotemii. The excess concentration of chlorine more than 30.3 mmol/l may lead to higher concentrations of chlorine in the plasma, the development of excitation, edema, heart rhythm and respiratory depression.
The glucose concentration less than 34 g/l can lead to a decrease in the concentration of glucose in the blood plasma, hypotonia, and coma. Excess glucose concentration of more than 34 g/l can lead to increased concentrations of glucose in plasma, the development of ketoacidosis, dehydration due to glycosuria and osmotic diuresis and impaired consciousness.
Concentration fumarata less than 14 mmol/l leads to a decrease in the content of gamma and immunoglobulin, antioxidant protection and immune responsiveness Concentration fumarata more than 14 mmol/l may cause times is the United nausea, pain in the epigastrium, vomiting, diarrhea, occurrence of dizziness, weakness, confusion and lowering blood pressure.
Thus, the claimed solution "Fazioli" is balanced by the content of electrolytes and glucose, does not violate the acid-base equilibrium and optimal for intravenous shortages and security physiological needs in the water and basic electrolytes.
In the table the values of the components of the proposed solution "Fazioli", if used to provide the daily physiological needs in the fluid (V), basic electrolytes and glucose depending on age in years (n) and body mass (MT).
|Age, body weight, daily fluid volume and the amount of electrolytes in mmol/kg/day using a solution "Fazioli"|
|* when calculating the volume of fluid according to the formula of Wallace - V ml/kg/day=100-3×n, where n is the age in years (but not more than 2.5 l/day).|
On the current data table and on the basis of physiological norms solution "Fazioli" can be adequately satisfy a physiological need in basic electrolytes.
Example 1. Patient K. East. disease No. 6948. Age 1 year. Arrived for treatment in the clinic SPbGPU 21.04.2013. Diagnosis: Congenital malformation. Cleft hard and soft palate. The issue is Lana operation: Uranoplasty.
In the perioperative period and in the first 2 days post-operative intensive care to ensure physiological water needs and basic electrolytes used the claimed solution "Fazioli" in the amount of one liter per day.
Daily biochemical blood analysis of the patient showed that the concentrations of major electrolytes and glucose in plasma were within normal values: sodium 138-140 mmol/l, potassium 3.9 to 4.0 mmol/l; ionized calcium 2.2 to 2.3 mmol/l; magnesium is 0.9 to 0.92 mmol/l; chlorine 101-104 mmol/l; glucose 4.2 to 4.5 mmol/l
Example 2. The Patient Century. East. disease No. 7413. Age 12 years. Arrived for treatment in the clinic SPbGPU 05.04.2013. Diagnosis: Bilateral pneumonia. To fill the gap and provide physiological water needs and basic electrolytes within 3 days of intensive therapy was administered the inventive solution "Fazioli" in a volume of 2.5 liters per day.
Daily monitoring of biochemical blood analysis showed that the concentrations of major electrolytes and glucose in plasma were within normal values: sodium 139-142 mmol/l; potassium of 3.7-3.9 mmol/l; ionized calcium 2.3 to 2.4 mmol/l; magnesium 0,92-0,94 mmol/l; chlorine 103-104 mmol/l; glucose is a 4.3-4.6 mmol/L.
Benefits of the solution "Fazioli" the following:
1) solution "Visioli contains balanced to ensure the physical and the logical needs of the concentrations of major electrolytes, it does not require for this purpose several infusion solutions;
2) the solution is safe for clinical use, as it is composed of chemicals that are used in combination for many decades and in many infusion solutions;
3) the solution can be used for diseases of different etiology;
4) the solution can be used for patients of any age;
5) use of the solution "Fazioli" cannot have a limit on the duration of use;
6) solution "Fazioli" its purpose is not absolute contraindications;
7) the relatively low concentration of sodium ions in solution "Visioli allows parallel with its introduction the use of other sodium solutions special purpose;
8) practical application solution "Fazioli" will reduce the number of complications of infusion therapy, will simplify the calculations in the preparation of infusion program and will reduce the risk of potential errors of the medical staff.
Infusion solution to fill the gap and provide physiological water needs and basic electrolytes containing chlorides of potassium, calcium, magnesium and glucose, wherein the concentration of the components is in mmol/l:
|Calcium (CA2+)||3,56-of 3.64|
|Water for injection||rest|
SUBSTANCE: invention refers to medicine and aims at intraoperative and early postoperative infusion therapy. A method involves administering a crystalloid balanced solution of sterofundin iso and a balanced colloidal solution of tetraspan. In the intraoperative period, sterofundin is administered with tetraspan in the volume ratio 3:1. In the early postoperative period, for the first day, sterofundin and tetraspan are administered in the volume ratio 6:1.
EFFECT: method is simple, safe, enables effectively correcting aqueous electrolyte disorders, stabilising systemic hemodynamic parameters, causing no negative effect on haemostasis and electrolyte composition of the blood serum.
1 ex, 1 tbl
SUBSTANCE: invention relates to a concentrated acid component for bicarbonate hemodialysis. The acid component includes sodium (Na+) in an amount of 2450.0-4550.0 mEq/l, chlorine (Cl-) in an amount of 2453.5-4553.5 mEq/l, hydrogen H+ (hydrochloric acid), succinate and citrate, each in an amount of 3.5-98.0 mEq/l. The invention also relates to a diluted acid component for bicarbonate hemodialysis, which includes sodium chloride 70.0-130.0 mEq/l, hydrochloric acid 0.1-2.8 mEq/l, succinic acid 0.1-2.8 mEq/l, and citric acid 0.1-2.8 mEq/l. The invention also relates to a concentrate for preparation of the acid component, which contains hydrochloric acid in a liquid form, and all other components in a dry form, as well as to a method of obtaining the acid component, which includes dissolution of dry chemical reagents from the said concentrate in water and addition of liquid reagents.
EFFECT: invention ensures obtaining a solution for dialysis, applied in case of acute and chronic renal failure.
14 cl, 1 tbl, 3 ex
SUBSTANCE: before transfusion, a preserved blood sample of 2 ml is mixed with an ozonised solution of 0.9% sodium chloride with the ozone concentration of 2 mg/l in the equivalent volume. The 15-minute exposition is followed by evaluating the 2,3 diphosphoglycerate concentration in the prepared packed red cell suspension. The 2,3 diphosphoglycerate concentration in the packed red cell suspension more than 6 mcmole/l testifies to the high effectiveness of planned hemotransfusion.
EFFECT: using the invention provides higher accuracy of determining the suitability of the preserved packed red cells for transfusion that ensures higher clinical effectiveness in the severe patients by fast and stable correction of oxygen delivery and consumption preferentially by functionally adequate red cells.
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to pharmaceutical industry and represents a formulation of a perfluorinated blood substitute emulsion for biomedical applications, containing: perfluorinated hydrocarbons, emulsifying agents and an electrolyte solution differing by the fact that it contains a binary mixture of two perfluorinated hydrocarbons in ratio 1.55 to 1.99 in the concentration of 5 - 1000 g/l, with an average particle size of a perfluororganic compound of 25 - 250 nm; a binary mixture of the emulsifying agents in ratio 1.55 to 1.99 that are non-ionic block copolymers of ethylene oxide and propylene oxide - proxanoles: proxanole-268/proxanole-168; proxanole-268 in the concentration of 1 - 200 g/l with the molecular weight of 7 - 14 thousand Da; proxanole-168 in the concentration of 1 - 200 g/l with the molecular weight of 5 - 7 thousand Da; the electrolyte solution: NaH2PO4 - 0.18-0.25 g/l; NaCl - 5.5-6.5 g/l; and/or KCl - 0.37-0.41 g/l; and/or MgCl2 - 0.17-0.21 g/l; and/or NaHCO3 - 0.35-0.7 g/l; and/or glucose - 1.5-2.5 g/l.
EFFECT: invention ensures formulating the perfluorinated blood substitute with better aggregation and sedimentation stability and lower toxicity.
2 cl, 9 ex
SUBSTANCE: invention relates to medicine, namely to surgery, anesthesiology and intensive therapy, oncology, and can be applied in operations on account of non-organ retroperitoneal tumours. For this purpose prognostic criteria are determined on the basis of clinical and anamnestic parameters: Long stands for longitudinal dimension of tumour, in cm; Transv stands for transverse dimension of tumour, in cm; Rad stands for radical character of operation: 1 point means presence of radical intervention; 0 points means absence, palliative surgery, exploratory laparotomy; AddRes means carrying out additional resection of organs: 1 point means presence of organ resection; 0 points means operation only on tumour ablation; PorS stands for surgery on main vessels: 1 point stands for vascular plasty of arteries, resection of fragments of inferior vena cava, aorta; DifG stands for diffusion growth of tumour without capsulation: 1 point means presence; 0 points means absence. After that, coefficient of regression Z is calculated: Z=-0.581+0.038×Long+0.02×Transv+0.073×Rad+0.166×AddRes+0.133×PorS+0.102×DifG and substituted into formula:
EFFECT: method makes it possible to select optimal tactics of compensation of intravascular volume of colloids in operations in said category of patients due to more accurate calculation of blood loss volume.
SUBSTANCE: invention relates to medicine, namely to intensive therapy and narcology, and can be used in treatment of patients with frostbites, who are in the state of narcotic intoxication of different severity. For this purpose determined are: area of affection, degree of frostbite, degree of narcotic intoxication, physiological needs of organism and pathological loss during a day. After that, volume of infusion therapy is calculated by formula: V=(Cfs×S)+(Cn×MVDIT)+PN+PL, where: V is volume of infusion therapy, in ml; Cfs is coefficient of frostbite severity: 1.0 in case of I and II degree frostbites; 2.0 in case of III-IV severity degree frostbite; S is area of affected surface, in cm2; Cn is coefficient of narcotic intoxication severity: 1.0 - in case of changed reactivity to narcotic substance; 1.5 - in case of psychic dependence (obsessive attraction); 2.0 - in case of physical dependence (compulsive attraction); 2.5 - in case of abstinence syndrome; MVDIT is minimal volume of disinfection infusion therapy in case of application of dezomorphin, equal to 1250 ml of infusion solutions per day; PN stands for physiological needs of organism during a day; PL stands for pathological loss during a day, constituting 500 ml in case of I and II degree of frostbites and 1000 ml in case of III and IV degree of frostbites.
EFFECT: method ensures adequate and differentiated performance of infusion therapy in said category of patients taking into account degree of narcotic intoxication, which contributes to prevention of "mutual aggravation", minimisation of disorders of hemostasis, microcirculation, as well as prevention of encephalopathy of complex genesis, including carrying out necrotomy and fasciotomy.
SUBSTANCE: invention relates to medicine, namely to surgery and intensive therapy, and can be used in treatment of patients with frostbites. For this purpose degree of frost bite severity, area of affection, physiological needs of organism and pathological loss during a day are determined. After that, volume of infusion therapy is calculated by formula: V-C×S+PN+PL, where: V is volume of infusion therapy, in ml; C is coefficient of frost bite severity: 1.0 in case of I and II degree frostbites; 2.0 in case of III-IV degree frostbites; S is the area of affected surface, in cm2; PN stands for physiological needs of organism during a day, in ml; PL stands for pathological loss during a day, in ml.
EFFECT: method ensures elimination of hemostasis and microcirculation disorders in pre-reactive period, as well as in early and late reactive periods due to carrying out adequate infusion therapy with optimal volume of solutions.
SUBSTANCE: invention relates to narcology, and can be used in treatment of patients with frost bites, who are in the state of alcoholic intoxication of different severity. For this purpose determined are: degree of frostbite, area of affection, degree of alcoholic intoxication, physiological needs of organism and pathological loss during a day. After that, volume of infusion therapy is calculated by formula: V=(CfsxS)+(CfxSVIT)+PN+PL, where: V is volume of infusion therapy, in ml; Cfs is coefficient of frost bite severity: 1.0 in case of I and II degree frost bites; 2.0 in case of III-IV severity degree frost bite; S is area of affected surface, in cm2; Ca is coefficient of alcoholic intoxication severity: 0.5 in case of mild degree, 0.75 in case of medium severity; 1.0 in case of severe degree; 1.5 - in case of alcoholic coma; SVIT is standardised volume of infusion therapy, in case of alcoholic intoxication equal 2500 ml per day: PN stands for physiological needs of organism for a day, in ml; PL stands for pathological loss within a day, in case of I and II degree frost bites constituting 500 ml; in case of III and IV degree frost bites constituting 1000 ml.
EFFECT: method ensures adequate and differentiated carrying out infusion therapy in said category of patients, taking into account degree of alcoholic intoxication, which contributes to prevention of "mutual aggravation" syndrome, minimisation of hemostasis and microcirculation, as well as prevention of encephalopathy of complex genesis, alcoholic psychosis, including cases after carrying out necrotomy and fasciotomy.
SUBSTANCE: invention relates to medicine, namely to resuscitation and intensive therapy and can be used in treatment of hemorrhagic shock of I, II and II degree of severity. Method of hemorrhagic shock treatment. For this purpose, assessment of degree of hemorrhagic shock severity is carried out, and in case of hemorrhagic shock of 1 degree of severity in the programme of infusion therapy included are: crystalloid solution of isotopic sterofundin in dose 3000 ml per day and 4% colloidal solution of modified gelatin in volume 1000 ml per day, in case of hemorrhagic shock of II degree of severity - 1200 and 2500 ml respectively, in case of hemorrhagic shock of III degree of severity - 1200 and 3500 ml respectively.
EFFECT: method makes it possible to improve results of treating patients with hemorrhagic shock at pre-hospital and hospital stages due to reduction of risk of electrolyte and acid-alkaline disorders.
SUBSTANCE: invention refers to medicine, namely resuscitation and may be used for prevention of severe complications in surgical management of massive and submassive blood loss with continuous haemorrhages. That is ensured by the intraoperative intravenous drop-by-drop introduction of Perftoran 2-4 ml/kg following mechanical arrest of the continuous haemorrhages. With underlying restorable blood volume, higher body oxygenation with eliminated nitrogen oxide inhalation. Rheamberyn is introduced in an average therapeutic dose at the end of the operation and on the first three postoperative days.
EFFECT: invention provides higher effectiveness of infusion-transfusion management, improved clinical course of the operative and postoperative period, reduced percentage of complications and mortality.
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to pharmaceutics and represents an injectable form of 5α-androstane-3β,5,6β-triol containing a liquid injectable form, containing a solvent, or a solid injectable form containing at least one soluble additive with the above at least one soluble additive containing hydroxypropyl-β-cyclodextrine.
EFFECT: invention provides preparing the stable injectable form of 5α-androstane-3β,5,6β-triol.
10 cl, 7 ex, 4 tbl
FIELD: medicine, pharmaceutics.
SUBSTANCE: claimed invention relates to an injection medical composition for local application in treatment of haemorrhoid, which contains hydroxychloroquine. In particular, the composition contains hydroxychloroquine in a physiological solution for injection with a local anaesthetic and an antioxidant.
EFFECT: injection composition by the invention ensures strengthening of haemorrhoid tissue for blocking metabolism in the haemorrhoid tissue, and as a result -necrosis of the haemorrhoid tissue.
5 cl, 8 dwg, 1 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: storage-stable pharmaceutical composition represents a liquid formulation containing bortezomib and a system of anhydrous solvents and applicable for injection. A primary ingredient of the system of anhydrous solvents is propylene glycol. Bortezomib is found in the concentration of at least 1 mg/ml. The pharmaceutical composition contains a total amount of aqueous buffer of 10 vol. % or more.
EFFECT: stable pharmaceutical composition according to invention maintains bortezomib degradation at the level of not less than 10 wt % when keeping the liquid formulation for at least three months in the ambient environment.
9 cl, 10 tbl
SUBSTANCE: invention represents an irrigation solution containing sodium chloride, mono- and dibasic sodium phosphate, glycosaminoglycans, glucose or its derivatives, water-soluble cellulose or its derivatives, neuraminic acid, an antihypertensive agent and water.
EFFECT: irrigation solution is balanced; it possesses the anti-inflammatory, anti-oedemic and antihypertensive properties.
SUBSTANCE: viscoelastic solution for the posterior hyaloid contrast enhancement contains a colouring agent, methyl cellulose, hyaluronic acid, low polyvinyl pyrrolidone and injectable water. The colouring agent is presented by trypan blue and/or brilliant blue. The ingredients are used in the declared ratio.
EFFECT: lower toxic effect of the retina, improved intraoperative visualisation of cortical layers of the vitreous body.
SUBSTANCE: group of inventions refers to veterinary science and aims at normalising metabolic processes, stimulating immune system and blocking mechanisms of infectious process with a risk of endogenous infection activation. A method for producing a combination immunometabolic preparation with anti-infectious activity involves dissolving succinic acid and levamisole in demineralised water with formalin added. According to the other aspect of the invention, the immunometabolic preparation additionally contains polyethylene glycol. The ingredients are used in the declared ratio.
EFFECT: using this group of inventions provides producing an injection form of the immunometabolic preparation with anti-infectious activity.
2 cl, 3 tbl
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to application of quaternary ammonium compounds, such as benzalkonium chloride, bromide, or iodide or benzethonium chloride, bromide or iodide as medication for prevention precipitation of pradofloxacin of formula
or its pharmaceutically acceptable salt or hydrate into sediment from solutions, containing pradofloxacin in amount 0.1-15% (wt/vol), bivalent cations of metals, such as cations of alkali earth metals in amount 0.5-5% (wt/vol), water and pH regulator - the remaining part, as well as medication with antibiotic action, which contains in dissolved form: pradofloxacin in amount 0.1-15% (wt/vol), quaternary ammonium compound, such as benzalkonium chloride, bromide, or iodide or benzethonium chloride, bromide or iodide, bivalent cations of metals, such as cations of alkali earth metals, in particular Mg2+, in amount 0.5-5% (wt/vol), water and pH regulator.
EFFECT: medication preserves stability for 5 years.
5 cl, 2 tbl, 8 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to the chemical-pharmaceutical industry and represents a method of obtaining a complex preparation for the application in veterinary, possessing immunomodulating and antiseptic properties, which includes mixing succinic acid, levamisole and formalin in distilled water with the following component ratio, wt %: levamisole - 3.0%-3.5%; succinic acid - 2.0%-2.5%; formalin - 0.3%-0.5%, distilled water - the remaining part; sterilisation of the solution by autoclaving is performed in a mode of 1 atm for 20 minutes.
EFFECT: elaboration of the method of obtaining the complex preparation for the application in veterinary, possessing immunomodulating and antiseptic properties.
SUBSTANCE: described is biomaterial, stimulating the anti-tumour activity, which contains lyophilisate of postnatal induced lymphatic nodes (PNILN) of a patient with cancer. Described is a preparation, stimulating the anti-tumour activity, which contains as an active substance lyophilisate of PNILN of the patient with cancer, and as a solvent, water for injections, cremofor RH-40, an emulsifier T-2, peach oil, glycerol, Kollidon CL-M and benzyl alcohol with the specified component ratio.
EFFECT: obtaining a novel preparation of domestic production, which contains biomaterial, stimulating the anti-tumour activity, possessing the expressed prolonged action, and convenient in application.
3 cl, 5 dwg, 3 ex
FIELD: food industry.
SUBSTANCE: invention relates to functional food products and represents a method for production of a non-aqueous health-improving product that is administrated in the form of drops and contains strain of lactic bacteria suspended in vegetable food oil; vegetable food oil is mixed with vitamin D; Lactobacillus rhamnosus GG lactic bacteria are suspended in the produced oil mixture.
EFFECT: invention ensures combination of beneficial effects of the proposed composition ingredients and easiness of the latter dosing during intake.
11 cl, 1 dwg, 1 ex
SUBSTANCE: upon completion of the surgical intervention, before the abdominal wall closure, microirrigators are inserted through counteropenings into the hypochondria. An end of the right microirrigator is fixed with an interrupted catgut suture to a stump of the resected stomach; an end of the left microirrigator is fixed at an upper level of the abdominal cavity with the interrupted catgut suture. Drain tubes are inserted through the counteropenings in the iliac regions into the small pelvis. The surgical intervention is terminated with treating the whole abdominal cavity with 50 ml ozonised normal saline 1000 mcg/l. Then 10 minutes later, the abdominal cavity is treated with metronidazole 100 ml. From the 1st to 5th postoperative day, metronidazole 200 ml is administered in the form of 24-hour infusion through a portable infusion device via the right microirrigator. Through the left microirrigator, 50 ml ozonised normal saline 1000 mcg/l is administered once a day. A course of standard intravenous antibiotic therapy is prescribed into the patient.
EFFECT: reducing an incidence rate of postoperative infectious-inflammatory complications in the given category of patients due to the specific regimen of the antibacterial therapy and the ozone therapy.